CorMedix (CRMD) Misses Q2 EPS by 2c

CorMedix (NYSE: CRMD) reported Q2 EPS of ($0.13), $0.02 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $16.51 million, versus $119.97 million reported last year.

For earnings history and earnings-related data on CorMedix (CRMD) click here.

You May Also Be Interested In

• Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
• Abivax reports Phase 3 maintenance trial results for obefazimod
• AeroVironment (AVAV) Tops Q4 EPS by 36c